HIV
TDM (Therapeutic Drug Monitoring) is the determination of drug concentrations
in different biological samples of human origin (plasma, serum, cerebro-spinal
fluid, urine etc.) with the objective of giving to the clinician useful data
to correctly manage the treatment.
Biostrands TDM ELISA technology is based on the competition between the drug in the biological sample and an analog of the same drug chemically conjugated to a revealing enzyme for the specific binding site on an antibody of animal origin.
BIOSTRANDS' METHOD
The Plasma sample from the patient to be monitored is diluted and mixed with the enzyme-conjugated drug. This mix is added to a microtitre plate well pre-absorbed with anti-rabbit immunoglobulins.
An antibody (from rabbit) specific for the drug to be monitored is added. A this time, the competition between the drug in the sample and the conjugated drug for the specific binding site starts. At the same time, the specific antibody is progressively immobilized on the solid phase by the binding with the anti-rabbit antibodies pre-absorbed on the microplate.
At the end of the reaction a washing step with a buffer solution is performed followed by the addition of a chromogenic substrate. The solid phase bound enzyme will convert the substrate to a coloured product; such colour can be read with a microplate photometre.
Higher the drug concentration in the sample, lower the enzyme conjugated drug which will be immobilized in the well with consequently lower colour formation photometrically detectable.
Presentation
Data Sheet
Amprenavir-Fosamprenavir English version
Nelfinavir
Ritonavir English version
Lopinavir English version
Bibliography